10.08.25 -- De-Risk And Accelerate Clinical Supply With Smarter CDMO Solutions

Join 1,000+ pharma, biotech, and drug delivery professionals at the PODD: Partnership Opportunities in Drug Delivery Conference conference, October 27–28 in Boston. Featuring 10 technology tracks, pharma company spotlights, 1:1 partnering, and more. Attendees will also hear from leaders at companies including AbbVie, Amgen, AstraZeneca, Biogen, Eli Lilly, GSK, Moderna, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, and others. Register at PODDConference.com with code LSL20 for 20% off.

From start to finish, NovaPure components have been designed and manufactured using Quality by Design principles to mitigate risk for the patient and improve success.

Learn how the right partner leverages experience, market knowledge, industry relationships, and clinical packaging expertise to develop a sourcing strategy tailored to unique study needs.

Accelerate your molecule from first-in-human to proof-of-concept with a fully integrated clinical pharmacology program, from study design to data reporting.

Speed-solutions combine value-added services and expertise, delivering an integrated approach, de-risking the supply chain by eliminating the need to transfer to alternative suppliers.

Liquid-filled hard-shell capsules offer these indisputable advantages in each phase of drug development.

Our stability storage and sample management capabilities serve the Pharmaceutical, Medical Device, and Life Sciences industries, with locations across North America and Europe.

Partner with our cGMP manufacturing facility to ensure seamless, high-quality scale-up from clinical development to commercial production of your biologics.

Experience cost savings, risk mitigation, logistics support, and streamlined communication by utilizing our international storage and sampling/dispensing services.

By leveraging the country's regulatory advantages and partnering with a New Zealand-based CDMO, international companies can easily accelerate approvals and navigate regulatory pathways.